Skip to main content

US equities: Assessing the ‘One Big, Beautiful Bill’

Trump’s ‘One Big, Beautiful Bill’ has narrowly passed its first hurdle in the House of Representatives. Artemis’ Chris Kent explores the implications of the wide-ranging bill as it makes its way through the Senate.

President Donald Trump’s economic policy began with a bang, marked by his liberal use of executive orders to impose tariffs on all of the US’s trading partners.

Whilst we can be criticised for initially underestimating the degree and breadth of the president’s use of tariffs, it would appear we are approaching what will be a manageable position for corporate America. However, our recent experience tells us we should not completely rule out negative surprises.

In President Trump’s mind, tariffs serve two purposes. First, he wants to use them as a stick to encourage businesses to relocate productive capacity back to the United States. In this endeavour, he is likely to use sector-specific tariffs quite liberally, for instance on semiconductors and parts of the pharmaceutical supply chain.

However, by definition, President Trump does not want everything to return to the US (if that were even possible) as he also needs the tax revenue generated by tariffs to help offset the tax cuts he has promised.

One Big, Beautiful Bill

This brings us to his next priority: enshrining into law his agenda on domestic taxation and spending, in what has become known as the One Big, Beautiful Bill. You can say what you like about the President, but there is no doubt that he does have a neat turn of phrase.

Trump has chosen to achieve this via a process called ‘budget reconciliation’, which requires a simple majority in both houses to pass. Given the Republicans have a – very narrow – majority in both houses, it should in theory not need the help of the Democrats to be pushed through.

So far, this has proved to be the case. On 22 May, after weeks of negotiations, the House of Representatives passed the bill by 215 votes to 214.

The bill now passes to the Senate, where the Republican majority is 53 versus the Democrats’ 47. Unlike the House, the Senate will be able to make changes to the bill. Initial indications are that these are likely to be substantial.

Tax cuts

Not surprisingly, cutting taxes will not generate that much controversy amongst Republican lawmakers. The first order of business will be to extend the personal tax cuts President Trump enacted during his first term, which are due to expire at the end of this year. He has also promised no taxation on tips and overtime.

Regarding corporate tax, President Trump campaigned on lowering the corporate tax rate on domestically generated profits to 15%. However, recently, this proposal has been shelved in favour of more investment-led taxation incentives.

These policies have the advantage of being a narrower tax giveaway but also coherent with the policy of encouraging domestic investment in production. Notable amongst the current suggestions are immediate tax breaks for R&D expenditure.

This is precisely the sort of policy we envisioned at the outset of this administration, as it will boost US investment, strengthen domestic companies and lead to increased high-value-added jobs in research and development, among other benefits.

The real tension lies in spending cuts

However, as we all know, giving away taxpayers’ money is much easier to do than taking away money from programmes which provide services to taxpayers ’for free’.

You may recall that during his first administration, President Trump repeatedly attempted to repeal ObamaCare, which had greatly expanded the number of people eligible for Medicaid (healthcare coverage for low-income individuals).

While there are a number of ideologues and fiscal conservatives who want to cut Medicaid expenditures dramatically, there are as many, possibly more, Republican Congresspeople who are highly aware of the number of their constituents who rely on this support and are pushing back hard against any cuts to Medicaid.

It is this disagreement over government expenditure which could mean that the president’s initial deadline of 4 July for passing this legislation is not met, and we should not rule out the possibility of the president needing the pressure of the calendar to force a resolution. The expiry of President Trump’s 2017 personal taxation cuts is something no Republican wants to see happen.

However, every administration is aware of the absolute necessity of avoiding its own Liz Truss moment; hence, the balance between tax cuts and spending cuts will need to be something that the market (by which I mean the bond market) can accept.

Moving in the right direction?

Whilst it has been a rollercoaster ride for markets since Trump’s inauguration, with somewhat of a false start to the ‘positives’ that the market was looking for in his presidency, we do believe we are moving towards more of a ‘good’ outcome that we were playing for at the start of the year.

We are cautiously optimistic that we will reach a coherent solution on tariffs as described above. We are also encouraged that the administration is attempting a joined-up policy using both carrot and stick to encourage domestic investment, policies which we think will be positive for the domestic economy. That being said, there is a narrow path to be negotiated between what’s good for the economy and what the bond market can accept.

Investment in a fund concerns the acquisition of units/shares in the fund and not in the underlying assets of the fund.

Reference to specific shares or companies should not be taken as advice or a recommendation to invest in them.

For information on sustainability-related aspects of a fund, visit the relevant fund page on this website.

For information about Artemis’ fund structures and registration status, visit artemisfunds.com/fund-structures

Any research and analysis in this communication has been obtained by Artemis for its own use. Although this communication is based on sources of information that Artemis believes to be reliable, no guarantee is given as to its accuracy or completeness.

Any statements are based on Artemis’ current opinions and are subject to change without notice. They are not intended to provide investment advice and should not be construed as a recommendation.

Third parties (including FTSE and Morningstar) whose data may be included in this document do not accept any liability for errors or omissions. For information, visit artemisfunds.com/third-party-data.

Important information
The intention of Artemis’ ‘investment insights’ articles is to present objective news, information, data and guidance on finance topics drawn from a diverse collection of sources. Content is not intended to provide tax, legal, insurance or investment advice and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security or investment by Artemis or any third-party. Potential investors should consider the need for independent financial advice. Any research or analysis has been procured by Artemis for its own use and may be acted on in that connection. The contents of articles are based on sources of information believed to be reliable; however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation is given as to its accuracy or completeness. Any forward-looking statements are based on Artemis’ current opinions, expectations and projections. Articles are provided to you only incidentally, and any opinions expressed are subject to change without notice. The source for all data is Artemis, unless stated otherwise. The value of an investment, and any income from it, can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.